Advancements in the application of reporter gene cell lines in bioactivity evaluation of biological products

Abstract

The assessment of biological product activity is a key aspect of quality control. Currently, in vitro assays serve as the primarily method employed by both companies and regulatory agencies to evaluate biological activity. Reporter Gene Assay (RGA) is a technique that investigates gene expression regulation and cellular signal transduction pathway activation through easily detectable reporter genes. RGA is highly dependent on drug mechanisms, offering high accuracy and precision, and has gained increasing recognition. The utilization of alternative analytical methods based on RGA have emerged as a prevailing trend, with a growing number of antibody drugs adopting corresponding RGA-based quality control approaches. Establishing stable expressing cell lines is essential to ensure the stability, reliability, and consistency of assays across diverse conditions when employing RGA techniques. CRISPR/Cas9 gene editing technology mediated site-specific gene integration allows for rapid and precise insertion of exogenous genes into specific genomic loci and enables the efficient construction of stable RGA cell lines, which would significantly propel the advancement of biological activity evaluation methods.

Keywords

Biological activity / Reporter gene assay / Stable cell line / CRISPR/Cas9 / Targeted integration

References

[1] Asmamaw MengstieM, Teshome AzezewM, Asmamaw DejenieT, TeshomeAA, Tadele AdmasuF, Behaile TeklemariamA, Tilahun MuluA, Mekonnen AgidewM, AdugnaDG, GeremewH, AbebeEC. Recent advancements in reducing the off-target effect of CRISPR-Cas9 genome editing. Biol Targets Ther, 2024, 18: 21-28.

[2] AzeezSS, HamadRS, HamadBK, ShekhaMS, BergstenP. Advances in CRISPR-Cas technology and its applications: revolutionising precision medicine. Front Genome Ed, 2024, 61509924.

[3] BaahS, LawsM, RahmanKM. Antibody-drug conjugates-a tutorial review. Mol (Basel Switzerland), 2021, 2610. 2943

[4] BlayV, TolaniB, HoSP, ArkinMR. High-throughput screening: today's biochemical and cell-based approaches. Drug Discov Today, 2020, 25(10): 1807-1821.

[5] BrowningJ, RooneyM, HamsE, TakahashiS, MizunoS, SugiyamaF, FallonPG, KellyVP. Highly efficient CRISPR-targeting of the murine Hipp11 intergenic region supports inducible human transgene expression. Mol Biol Rep, 2020, 47(2): 1491-1498.

[6] CalabrettaMM, MicheliniE. Current advances in the use of bioluminescence assays for drug discovery: an update of the last ten years. Expert Opin Drug Discov, 2024, 19(1): 85-95.

[7] CapelliD, ScognamiglioV, MontanariR. Surface plasmon resonance technology: recent advances, applications and experimental cases. TrAC Trends Anal Chem, 2023.

[8] ChenW, PandeyM, SunH, RolongA, CaoM, LiuD, WangJ, ZengL, HunterA, LinS. Development of a mechanism of action-reflective, dual target cell-based reporter bioassay for a bispecific monoclonal antibody targeting human CTLA-4 and PD-1. Mabs, 2021, 131. 1914359

[9] Chun-YuL, XinW, Chuan-FeiY, Gang-lingX, LanW. Development and application of ADCC biological activity assay method of anti-HER2 monoclonal antibody based on reporter genes. Chin J Pharmaceu Anal, 2019.

[10] CirincioneA, SimpsonD, YanW, et al.. A benchmarked, high-efficiency prime editing platform for multiplexed dropout screening. Nat Methods, 2025, 22: 92-101.

[11] European Medicines Agency (EMA) (1999) ICH Q6B, specifications: test procedures and acceptance criteria for biotechnological/biological products. https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-6-b-test-procedures-and-acceptance-criteria-biotechnologicalbiological-products-step-5_en.pdf

[12] GaoT, WangP, GongT, ZhouY, WangA, TangX, SongX, FanY. Reporter genes for brain imaging using MRI, SPECT and PET. Int J Mol Sci, 2022, 23158443.

[13] GolmSK, HübnerW, MüllerKM. Fluorescence microscopy in adeno-associated virus research. Viruses, 2023, 1551174.

[14] GrossenbacherP, EssersMC, MoserJ, SingerSA, HäuslerS, StiegerB, RougierJS, LochnerM. Bioorthogonal site-selective conjugation of fluorescent dyes to antibodies: method and potential applications. RSC Adv, 2022, 12(44): 28306-28317.

[15] GuJ, RolloB, SumerH, CromerB. Targeting the AAVS1 site by CRISPR/Cas9 with an inducible transgene cassette for the neuronal differentiation of human pluripotent stem cells. Methods Mol Biol (Clifton NJ), 2022, 2495: 99-114.

[16] GuptaRK. The vital role of biological standardization in ensuring efficacy and safety of biological products - historical perspectives. J Pharm Sci, 2025, 114(2): 690-700.

[17] Hong-MeiZ, FengZ, Chun-YuL, Chuan-FeiY, Mao-QinD, Jun-XiaC, LanW. Development and validation of a cell-based reporter gene assay for bioactivity determination of anti-EpCAM + CD3 bispecific antibody. Chin J New Drugs, 2021.

[18] HryhorowiczM, LipińskiD, ZeylandJ. Evolution of CRISPR/Cas systems for precise genome editing. Int J Mol Sci, 2023, 241814233.

[19] HuangY, LuY, LiuX, ChaiM, YangL, YinK, HeJ, WangZ, ZhangY, YuY, QiuS, FanY, LiZ. A portable all-in-one microfluidic platform integrated with CRISPR-based extraction-free assay for rapid and on-site detection of monkeypox and lumpy skin disease. Sens Actuators B Chem, 2025.

[20] HubT, CorneanA, RoundK, FlemingT, FreichelM, MedertR. Streamlined generation of CRISPR/Cas9-mediated single-cell knockout clones in murine cell lines. ACS Pharmacol Transl Sci, 2024, 7(5): 1291-1301.

[21] JiangC, LinX, ZhaoZ. Applications of CRISPR/Cas9 technology in the treatment of lung cancer. Trends Mol Med, 2019, 25(11): 1039-1049.

[22] KattiA, DiazBJ, CaragineCM, SanjanaNE, DowLE. CRISPR in cancer biology and therapy. Nat Rev Cancer, 2022, 22(5): 259-279.

[23] KawabeY, KomatsuS, KomatsuS, MurakamiM, ItoA, SakumaT, NakamuraT, YamamotoT, KamihiraM. Targeted knock-in of an scFv-Fc antibody gene into the hprt locus of Chinese hamster ovary cells using CRISPR/Cas9 and CRIS-PITCh systems. J Biosci Bioeng, 2018, 125(5): 599-605.

[24] KomatsuN, TeraiK, ImanishiA, KamiokaY, SumiyamaK, JinT, OkadaY, NagaiT, MatsudaM. A platform of BRET-FRET hybrid biosensors for optogenetics, chemical screening, and in vivo imaging. Sci Rep, 2018, 818984.

[25] LeH, VishwanathanN, JacobNM, GadgilM, HuWS. Cell line development for biomanufacturing processes: recent advances and an outlook. Biotechnol Lett, 2015, 37(8): 1553-1564.

[26] LeiY, YongZ, JunzhiW. Development and application of potency assays based on genetically modified cells for biological products. J Pharm Biomed Anal, 2023, 230. 115397

[27] LiYM, TianZW, XuDH, WangXY, WangTY. Construction strategies for developing expression vectors for recombinant monoclonal antibody production in CHO cells. Mol Biol Rep, 2018, 45(6): 2907-2912.

[28] LiH, YangY, HongW, HuangM, WuM, ZhaoX. Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects. Signal Transduct Target Ther, 2020, 511.

[29] LiM, WangL, YuC, WangJ. Development of a robust reporter gene assay for measuring the bioactivity of OX40-targeted therapeutic antibodies. Lumin J Biol Chem Lumin, 2021, 36(4): 885-893.

[30] LiangY, ZhangT. Guidelines for HTRF technology in EGFR kinase assay. eFood, 2022.

[31] LiuC, YuC, YangY, HuangJ, YuX, DuanM, WangL, WangJ. Development of a novel reporter gene assay to evaluate antibody-dependent cellular phagocytosis for anti-CD20 therapeutic antibodies. Int Immunopharmacol, 2021, 100. 108112

[32] LoughranG, AndreevDE, TereninIM, NamyO, MiklM, YordanovaMM, McManusCJ, FirthAE, AtkinsJF, FraserCS, IgnatovaZ, IwasakiS, KufelJ, LarssonO, LeidelSA, MankinAS, MariottiM, TanenbaumME, TopisirovicI, Vázquez-LaslopN, VieroG, CaliskanN, ChenY, ClarkPL, DinmanJD, FarabaughPJ, GilbertWV, IvanovP, KieftJS, MühlemannO, SachsMS, ShatskyIN, SonenbergN, SteckelbergA-L, WillisAE, WoodsideMT, ValasekLS, DmitrievSE, BaranovPV. Guidelines for minimal reporting requirements, design and interpretation of experiments involving the use of eukaryotic dual gene expression reporters (MINDR). Nat Struct Mol Biol, 2025.

[33] MaJ, MoY, TangM, ShenJ, QiY, ZhaoW, HuangY, XuY, QianC. Bispecific antibodies: from research to clinical application. Front Immunol, 2021, 12. 626616

[34] MacGillavryHD. Recent advances and challenges in the use of CRISPR/Cas9 genome editing for understanding neuronal cell biology. Neurophotonics, 2023, 104. 044403

[35] MajeresLE, DilgerAC, ShikeDW, McCannJC, BeeverJE. Defining a haplotype encompassing the LCORL-NCAPG locus associated with increased lean growth in beef cattle. Genes, 2024, 155576.

[36] MajumdarS, DesaiR, HansA, DandekarP, JainR. From efficiency to yield: exploring recent advances in CHO cell line development for monoclonal antibodies. Mol Biotechnol, 2025, 67(2): 369-392.

[37] MandóP, RiveroSG, RizzoMM, PinkaszM, LevyEM. Targeting ADCC: a different approach to HER2 breast cancer in the immunotherapy era. Breast (Edinburgh, Scotland), 2021, 60: 15-25.

[38] MiuraH, NakamuraA, KurosakiA, KotaniA, MotojimaM, TanakaK, KakutaS, OgiwaraS, OhmiY, KomabaH, SchilitSLP, MortonCC, GurumurthyCB, OhtsukaM. Targeted insertion of conditional expression cassettes into the mouse genome using the modified i-PITT. BMC Genomics, 2024, 251568.

[39] MorathV, FritschleK, WarmuthL, AnneserM, DötschS, ŽivanićM, KrumwiedeL, BöslP, BozogluT, RobuS, LibertiniS, KossatzS, KupattC, SchwaigerM, SteigerK, BuschDH, SkerraA, WeberWA. PET-based tracking of CAR T cells and viral gene transfer using a cell surface reporter that binds to lanthanide complexes. Nat Biomed Eng, 2025.

[40] NakashibaT, OgohK, IwanoS, SugiyamaT, Mizuno-IijimaS, NakashimaK, MizunoS, SugiyamaF, YoshikiA, MiyawakiA, AbeK. Development of two mouse strains conditionally expressing bright luciferases with distinct emission spectra as new tools for in vivo imaging. Lab Anim, 2023, 52(10): 247-257.

[41] NidhiS, AnandU, OleksakP, TripathiP, LalJA, ThomasG, KucaK, TripathiV. Novel CRISPR-Cas systems: an updated review of the current achievements, applications, and future research perspectives. Int J Mol Sci, 2021, 2273327.

[42] PengH, EndoY, WuWJ. Define critical parameters of trastuzumab-mediated ADCC assays via assay optimization processes, focusing on the impact of cryopreserved effector cells on assay performance. Cancers, 2024, 16132367.

[43] PiedeN, BremmM, FarkenA, PfeffermannL-M, CappelC, BonigH, FingerhutT, PuthL, VogelsangK, PeineltA, MarschalekR, MüllerM, BaderP, KuçiZ, KuçiS, HueneckeS. Validation of an ICH Q2 compliant flow cytometry-based assay for the assessment of the inhibitory potential of mesenchymal stromal cells on T cell proliferation. Cells, 2023, 126850.

[44] RegisterAC, TarighatSS, LeeHY. Bioassay development for bispecific antibodies—challenges and opportunities. Int J Mol Sci, 2021, 22105350.

[45] SahooN, CuelloV, UdawantS, LitifC, MustardJA, KeniryM. CRISPR-Cas9 genome editing in human cell lines with donor vector made by Gibson assembly. Methods Mol Biol (Clifton NJ), 2020, 2115: 365-383.

[46] ShapiroDM, DeshpandeS, EghtesadiSA, ZhongM, FontesCM, FiflisD, RohmD, MinJ, KaurT, PengJ, NeyM, SuJ, DaiY, AsokanA, GersbachCA, ChilkotiA. Synthetic biomolecular condensates enhance translation from a target mRNA in living cells. Nat Chem, 2025, 17(3): 448-456.

[47] SinghC, Roy-ChowdhuriS. Quantitative real-time PCR: recent advances. Methods Mol Biol (Clifton NJ), 2016, 1392: 161-176.

[48] SinghS, KachhawahaK, SinghSK. Comprehensive approaches to preclinical evaluation of monoclonal antibodies and their next-generation derivatives. Biochem Pharmacol, 2024, 225. 116303

[49] SmirnovAV, KontsevayaGV, ShnaiderTA, YunusovaAM, FeofanovaNA, GerlinskayaLA, SerovaIA, SerovOL, BattulinNR. Evaluation of the α-casein (CSN1S1) locus as a potential target for a site-specific transgene integration. Sci Rep, 2022, 1217983.

[50] UddinF, RudinCM, SenT. CRISPR gene therapy: applications, limitations, and implications for the future. Front Oncol, 2020, 101387.

[51] WangX, AnZ, LuoW, XiaN, ZhaoQ. Molecular and functional analysis of monoclonal antibodies in support of biologics development. Protein Cell, 2018, 9(1): 74-85.

[52] WangL, YuC, WangJ. Development of reporter gene assays to determine the bioactivity of biopharmaceuticals. Biotechnol Adv, 2020, 39. 107466

[53] WardynJD, ChanASY, JeyasekharanAD. A robust protocol for CRISPR-Cas9 gene editing in human suspension cell lines. Curr Protocol, 2021, 111. e286

[54] YangP, ZhangS, HuD, LiX, GuoY, GuoH, ZhangL, DingX. Research progress on the mechanism and application of the type I CRISPR-Cas system. Int J Mol Sci, 2024, 252312544.

[55] YuB, YangH. Evaluation of different estimation methods for accuracy and precision in biological assay validation. PDA J Pharm Sci Technol, 2017, 71(4): 297-305.

[56] ZehN, SchmidtM, SchulzP, FischerS. The new frontier in CHO cell line development: from random to targeted transgene integration technologies. Biotechnol Adv, 2024, 75. 108402

[57] ZengW, GuoL, XuS, ChenJ, ZhouJ. High-throughput screening technology in industrial biotechnology. Trends Biotechnol, 2020, 38(8): 888-906.

[58] ZhangML, LiHB, JinY. Application and perspective of CRISPR/Cas9 genome editing technology in human diseases modeling and gene therapy. Front Genet, 2024, 151364742.

[59] ZhuX, GongL, QinQ. Development, methodological evaluation and application of a cell-based TRF assay for analysis of ADCC activity. J Pharm Biomed Anal, 2023, 235. 115655

[60] ZouS, SunY, TangW. Charting the development and engineering of CRISPR base editors: lessons and inspirations. Cell Chem Biol, 2025.

RIGHTS & PERMISSIONS

The Author(s)